Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 studyMarina Chiara Garassino, Inmaculada Ramos García, Byoung Chul Cho et al.|The Lancet Oncology|2018Cited by 579
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trialsSolange Peters, Mary O’Brien, Baktiar Hasan et al.|Lung Cancer|2021Cited by 9